Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?
Open Access
- 1 February 2013
- journal article
- Published by H1 Connect in F1000 Medicine Reports
- Vol. 5 (4), 4
- https://doi.org/10.3410/m5-4
Abstract
Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?Keywords
This publication has 43 references indexed in Scilit:
- Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK studyJournal of Clinical Pathology, 2012
- Antigen Binding Characteristics of Immunoglobulin Free Light Chains: Crosslinking by Antigen is Essential to Induce Allergic InflammationPLOS ONE, 2012
- Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General PopulationMayo Clinic Proceedings, 2012
- Immunoglobulin Free Light Chains Are Increased in Hypersensitivity Pneumonitis and Idiopathic Pulmonary FibrosisPLOS ONE, 2011
- Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activityClinical Rheumatology, 2011
- Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activityAnnals Of The Rheumatic Diseases, 2010
- Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohortArthritis Research & Therapy, 2009
- Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2008
- Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2006
- Clinical relapse in systemic lupus erythematosus: Correlation with antecedent elevation of urinary free light-chain immunoglobulinJournal of Clinical Immunology, 1989